VXRT News and Press, Vaxart Inc. From 05/04/21

Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year Study results may inform the COVID-19 oral vaccine program SOUTH SAN FRANCISCO, Calif., May 0...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning and welcome to another busy day of trading on the stock market. We’re keeping up with the latest trading trends as we check out the biggest pre-market stock movers for Tuesday morning. Source: Eric U...

New data obtained from Vaxart's (VXRT) Phase I COVID-19 trial suggests that its oral coronavirus vaccine, VXA-CoV2-1, triggers mucosal immunity, includes both S and N SARS-Cov-2 proteins, and has broad cross-coronavirus activity. phase I data were compared to the data from volunteers subseque...

Vaxart oral vaccine induced higher CD8 + T-Cell responses than those seen with Moderna or Pfizer vaccines in comparative experiment conducted by the Company IgA antibodies triggered in the mucosa, show broad cross-reactivity SOUTH SAN FRANCISCO, Calif., May 03,...

Gainers: Precipio (PRPO) +102%.Regional Health Properties (RHE) +94%.American Shared Hospital Services (AMS) +33%.Brooklyn ImmunoTherapeutics (BTX) +26%.Scully Royalty (SRL) +25%.Ocugen (OCGN) +23%.Top Ships (TOPS) +23%.Rezolute (RZLT) +20%.Milestone Scientific (MLSS) +19%.Ashford H...

Vaxart (VXRT) shares slide over 12% during premarket trading after the company posted first-quarter results that missed Wall Street estimates, owing to higher research and development costs and a fall in Inavir related royalty revenue.The company's quarterly revenue plummeted over 8...

Vaxart (VXRT): Q1 GAAP EPS of -$0.14 misses by $0.04.Revenue of $0.51M (-82.4% Y/Y) misses by $0.11M.Shares -8.16% PM.Press Release For further details see: Vaxart EPS misses by $0.04, misses on revenue

Vaxart to advance three oral tablet COVID-19 vaccine candidates to the clinic: VXA-CoV2-1 (includes both the S and the N proteins) into Phase II and two S-only constructs into Phase I/II Four clinical trials of the oral norovirus vaccine candidate to be initiated in 2021 ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back and good morning! It’s the start of the week and that means it’s time for investors to get back into the game. We’re here to help with that as we take a look at the biggest pre-market stock...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...